Medeze Group Public Company Limited (SET: MEDEZE) has announced that its wholly owned subsidiary, Medeze Treasury Pte. Ltd. (MT), is making a significant investment through a voluntary conditional cash partial offer. The target of this offer is Cordlife Group Limited, a company incorporated in a foreign country and listed on the Singapore Exchange (SGX).
The offer, approved by the Medeze Group Board of Directors on 12 May 2025, aims to acquire 25,630,774 shares in Cordlife Group Limited. These shares represent 10 percent of the total shares in Cordlife Group Limited (excluding treasury stock).
MT is proposing to pay Singapore Dollar 0.25 in cash for each Offer Share. The total value of this partial offer is approximately Baht 165 million. Payment will be made in cash directly to Cordlife Group Limited’s shareholders who choose to accept the offer.
The transaction is expected to take place within July 2025. The investment aligns with MT’s objective to invest through financial instruments, including acquiring common shares in foreign stock exchanges, to seek the best returns within the framework of Medeze Group’s Investment Policy.
Funding for this transaction will come from an increase in the registered capital of MT. As MT’s shareholder, Medeze Group has approved the transfer of funds to increase MT’s capital, also in line with a resolution from the 2025 Annual General Meeting of Shareholders.
About Cordlife Group
Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, owns and operates Asia’s largest network of private cord blood banks. The Group is committed to ensuring the health and well-being of both mother and child, amongst others. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia with extensive transplant experience, having processed and stored more than 400,000 cord blood, cord lining, cord tissue, and placenta stem cell samples.
Cordlife is an industry leader in Hong Kong, Indonesia, and the Philippines and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. In addition to cord blood, cord lining, cord tissue, and placenta banking, Cordlife offers families a comprehensive suite of clinical diagnostics, including non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening. Cordlife strives to ensure reliable quality and is committed to a customer-centric approach.
